Abstract: An example power tool includes a battery pack receiving portion including a battery pack compartment including a battery pack support structure configured to receive and support a battery pack including battery terminals. The power tool further includes a terminal block located in the battery pack receiving portion and including tool terminals. At least two terminals of the tool terminals are configured to electrically and physically couple to the battery terminals. The power tool further includes an insertable device compartment located in the battery pack receiving portion and configured to receive an insertable wireless communication device including a first electronic processor, a transceiver, and device terminals. At least one device terminal is configured to electrically and physically couple to at least one shared terminal of the at least two terminals of the tool terminals. The insertable wireless communication device is configured to wirelessly communicate with an external device.

Abstract: The present disclosure provides a formulation comprising a fluoroolefin, an amine neutralizer, a fixative polymer, and a solvent. The formulation may be trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)), and the amine neutralizer may be triethanolamine (TEA), triisopropanolamine (TIPA), or a mixture thereof. The formulation may be suitable for use as a personal care product, such as a hair spray.

Abstract: A medical device system for delivering a neuromodulation therapy includes a delivery tool for deploying an implantable medical device at a neuromodulation therapy site. The implantable medical device includes a housing, an electronic circuit within the housing, and an electrical lead comprising a lead body extending between a proximal end coupled to the housing and a distal end extending away from the housing and at least one electrode carried by the lead body. The delivery tool includes a first cavity for receiving the housing and a second cavity for receiving the lead. The first cavity and the second cavity are in direct communication for receiving and deploying the housing and the lead coupled to the housing concomitantly as a single unit.

Abstract: An example power tool includes a battery pack receiving portion including a battery pack compartment including a battery pack support structure configured to receive and support a battery pack including battery terminals. The power tool further includes a terminal block located in the battery pack receiving portion and including tool terminals. At least two terminals of the tool terminals are configured to electrically and physically couple to the battery terminals. The power tool further includes an insertable device compartment located in the battery pack receiving portion and configured to receive an insertable wireless communication device including a first electronic processor, a transceiver, and device terminals. At least one device terminal is configured to electrically and physically couple to at least one shared terminal of the at least two terminals of the tool terminals. The insertable wireless communication device is configured to wirelessly communicate with an external device.

Abstract: An ostomy leakage detection system includes a sensing accessory, a wearable subsystem, a charging dock, and a mobile application. The sensing accessory includes a sensor region comprising a plurality of sensors for measuring resistance of an ostomy appliance, a connector region for connecting to the wearable subsystem, and a tail region extending between the sensor region and the connector region.

Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: The present invention relates to tetraaryl methyl amine compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: There is disclosed improved apparatus and methodology for customizing software. With respect to GUI resources such as splash-screens, a dynamic link library containing a customer's customized resources and a default link library containing the manufacturer's default resources are prepared at design time. Source code is normally not included in the customized dynamic link library. At run time, the customer resources are automatically included by operation of a resource manager algorithm and appear on the computer terminal screen unless they were not made available initially in which case the equivalent default resource is shown on the screen. If there are any bugs which are induced by the customer's specifications to be corrected, or if the customized dynamic link library is changed for some other reason, the source code does not have to be rewritten as it is not included in the dynamic link library.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Abstract: The present invention is directed toward a GGTase-I competitive binding assay which can be used to determine the relative GGTase-I inhibitory potency of test compounds. The present invention is also directed toward radiolabeled geranylgeranyl-protein transferase type-I inhibitor compounds which are useful to label GGTase-I in assays, whether cell-based, tissue-based or in whole animal.

Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

Abstract: The present invention comprises piperazine-containing compounds which inhibit prenyl-protein transferases, including-farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.

Abstract: The present invention comprises unsubstituted and substituted piperazine-containing compounds having alkanoyl, alkylsulfonyl, alkylamido or alkoxycarbonyl substituents, and having the formula A, which inhibit prenyl-protein transferases. In particular, the invention relates to prenyl-protein transferase inhibitors which are efficacious in vivo as inhibitors of geranylgeranyl-protein transferase type I (GGTase-I) and that inhibit the cellular processing of both the H-Ras protein and the K4B-Ras protein. Such therapeutic compounds are useful in the treatment of cancer.

Abstract: The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer.